Understanding Chronic Illness Means Embracing Complexity in Medical Research
The people have spoken. HHS must be reformed.
In the wake of Robert F. Kennedy Jr.'s decisive win as Donald Trump's backer in the 2024 presidential election, the Make America Healthy Again (MAHA) initiative has emerged as a transformative force in public health policy. With its ambitious goal to tackle the epidemic of chronic illness afflicting millions of Americans, MAHA marks a bold departure from the symptom-focused, piecemeal approaches of the past. It challenges researchers, clinicians, and policymakers to rethink the very foundations of how we understand and address disease.
At the heart of MAHA is a recognition that traditional tools like epidemiology, long regarded as the bedrock of public health research, are insufficient for unraveling the complexities of chronic disease. Epidemiology, though invaluable in identifying broad associations, is a blunt instrument when applied to the intricate interplay of factors that define conditions like diabetes, autoimmune disorders, and cardiovascular disease. Its reliance on two-factor association studies—asking whether Gene X increases the risk of Disease Y or whether Drug A reduces the incidence of Condition B—oversimplifies the multifactorial reality of chronic illness. Chronic diseases are not static or linear; they are dynamic systems shaped by countless interactions across biological, behavioral, and environmental domains.
(Considering upgrading to paid? Please pitch in!)
Take diabetes, for example. Its progression is not merely a function of insulin resistance; it emerges from a web of systemic inflammation, hormonal imbalances, gut microbiota disruptions, and environmental triggers. Yet much of the research on diabetes focuses on isolated factors, such as blood sugar levels or single genetic mutations, failing to account for how these elements interact. Even more egregiously, drug development often neglects the reality that patients with chronic illnesses typically take multiple medications simultaneously, leading to unforeseen drug x drug interactions. Similarly, genetic predispositions are rarely studied in combination, leaving genetic x genetic interactions—and their potential to amplify or mitigate disease risk—woefully unexplored. These oversights illustrate the inadequacy of simplistic, linear models in addressing diseases that are inherently nonlinear.
The limitations of these approaches extend beyond academic oversight; they have real-world consequences. By ignoring the complex feedback loops that drive disease progression, current research risks developing interventions that treat symptoms rather than root causes. Chronic hyperglycemia in diabetes, for instance, triggers feedback loops where elevated glucose damages beta cells, reducing insulin production and further worsening glucose control. Breaking such cycles requires more than addressing hyperglycemia alone; it demands a systems-level understanding of how metabolic, immune, and hormonal pathways converge and reinforce one another.
The MAHA mandate recognizes the urgent need to shift from reductionist paradigms to a framework rooted in complexity science. Chronic diseases do not arise from isolated causes but from systems where small changes can ripple across networks, creating effects that are nonlinear, emergent, and often unpredictable. Addressing these diseases requires a new toolkit: network-based medicine to map interactions between genes, proteins, and environmental factors; real-time monitoring to track how systems respond dynamically to interventions; and multifactorial intervention studies that test combinations of drugs, lifestyle changes, and genetic modifiers simultaneously.
This paradigm shift is not optional. Without embracing complexity, the promise of MAHA will remain unfulfilled, and the burden of chronic illness will continue to grow. The success of this initiative depends on our willingness to abandon outdated approaches and to invest in understanding disease as a dynamic, interconnected phenomenon. Only by confronting the full complexity of chronic illness can we hope to achieve a healthier, more resilient future.
The Nature of Complexity in Chronic Illness
Understanding chronic illness requires confronting the intricate web of interactions, feedback loops, and emergent behaviors that define its complexity. Unlike acute diseases with clear etiologies, chronic illnesses are not isolated phenomena. They arise from disruptions in entire networks of biological, environmental, and social factors. Complexity, in this context, refers to the way systems composed of many interdependent components generate behaviors and outcomes that cannot be predicted or explained by examining individual elements in isolation.
Chronic illnesses are the epitome of this interconnectedness. They represent a shift from a state of health to a state of dysfunction driven by nonlinear, multifactorial interactions. These disruptions often span multiple systems, such as metabolism, immunity, and the microbiome, and are shaped by external influences like diet, stress, and environmental exposures. As such, traditional reductionist models fail to capture the full scope of these diseases, necessitating a systems-level approach to their study and management.
Defining Complexity in Chronic Illness
Complexity arises from three key features:
Interacting Components: The systems involved in chronic illnesses comprise myriad elements—cells, signaling molecules, genes, and external factors—that influence one another in dynamic and sometimes unpredictable ways.
Feedback Loops: Chronic illnesses often involve self-reinforcing feedback mechanisms that drive disease progression. For example, elevated glucose in diabetes damages beta cells, reducing insulin production and further worsening glucose control.
Emergent Behaviors: These are properties that arise from the interactions of the system’s components but are not reducible to any single part. In chronic illness, emergent behaviors include tipping points, where incremental changes suddenly lead to systemic breakdown, and compensatory adaptations that stabilize one system while destabilizing another.
Examples of Complexity in Chronic Illness
The interconnected nature of chronic diseases can be illustrated through several examples, each demonstrating how disruptions in one system cascade across others.
Diabetes
Diabetes exemplifies complexity through its interactions between metabolic, immune, and environmental factors:
Insulin Resistance: Often triggered by excess nutrient intake and sedentary behavior, insulin resistance is not merely a metabolic defect but an inflammatory state. Adipose tissue dysfunction releases pro-inflammatory cytokines, which impair insulin signaling in muscle and liver cells.
Gut Microbiota: Dysbiosis, or an imbalance in gut microbes, exacerbates systemic inflammation and alters glucose metabolism, contributing to the progression of insulin resistance.
Lifestyle Factors: Stress, sleep deprivation, and poor diet amplify these physiological disruptions, creating a feedback loop where metabolic dysfunction and behavioral patterns reinforce one another.
Cardiovascular Disease
Cardiovascular disease is a prime example of how complexity emerges from the interplay of multiple systems:
Cholesterol Metabolism: Elevated low-density lipoprotein (LDL) cholesterol interacts with endothelial cells, triggering immune responses that lead to plaque formation.
Inflammation: Chronic low-grade inflammation, fueled by obesity or autoimmune conditions, accelerates atherosclerosis, the underlying process of most cardiovascular diseases.
Genetic Predisposition: Genetic variations in lipid metabolism and clotting factors further modify risk, demonstrating how inherited traits integrate into systemic dysfunction.
Autoimmune Disorders
Autoimmune diseases such as rheumatoid arthritis and lupus highlight the complexity of immune regulation:
Immune Dysregulation: Genetic predispositions combine with environmental triggers, such as infections or pollutants, to disrupt the balance between immune activation and suppression.
Epigenetics: Changes in gene expression caused by environmental influences, rather than alterations in the DNA sequence itself, add another layer of complexity to disease susceptibility and progression.
Feedback from Chronic Inflammation: Sustained inflammation damages tissues, releasing self-antigens that further provoke immune responses, perpetuating a vicious cycle.
Chronic illnesses defy simplistic explanations because they are born from the complex interactions of biological, environmental, and social systems. These diseases are not merely the sum of their parts but are shaped by feedback loops, emergent behaviors, and nonlinear dynamics. To address them effectively, medical research must transcend reductionist approaches and embrace the interconnected realities that define chronic illness. This understanding forms the foundation for rethinking prevention, treatment, and policy interventions in the context of complexity.
Why Reductionism Alone Falls Short
The biomedical sciences have long relied on reductionism—the idea that complex systems can be understood by breaking them into simpler, discrete parts. While reductionism has been instrumental in advancing molecular biology and identifying specific disease markers, its utility diminishes in the face of chronic illnesses. These conditions arise from multifactorial and interconnected systems, where the whole cannot be fully understood by analyzing its individual components. Reductionist approaches fail to capture the dynamic feedback loops, emergent behaviors, and systemic interactions that define chronic diseases. The result is a fragmented understanding of health and disease, with interventions often targeting symptoms rather than underlying causes.
The Oversimplification of Chronic Disease
Reductionist models typically frame chronic diseases as the result of isolated factors—be they genetic mutations, environmental exposures, or single biological pathways. This approach ignores the reality that diseases like diabetes, cardiovascular disease, and autoimmune disorders are shaped by the interactions between multiple systems. For instance, identifying a genetic variant associated with increased disease risk may provide insight into susceptibility but does little to explain how that gene interacts with lifestyle factors, immune responses, and metabolic pathways to produce clinical outcomes.
Epidemiology, which has traditionally driven public health policy, often compounds this problem. Two-factor association studies—designed to investigate whether a single exposure correlates with a particular outcome—are ill-suited for exploring the complexity of chronic diseases. They ignore the nonlinear and synergistic interactions between variables, leading to oversimplified conclusions. For example, studies examining the impact of diet on cardiovascular disease often fail to account for the role of gut microbiota, inflammatory markers, and genetic predispositions in modulating risk.
Reductionism in Drug Development
The limitations of reductionism are perhaps most evident in the pharmaceutical industry. Drugs are typically designed to target specific molecules or pathways, such as lowering blood sugar in diabetes or reducing cholesterol in cardiovascular disease. While these approaches can alleviate symptoms, they rarely address the systemic dysregulation that drives disease progression.
Consider the case of diabetes. Medications like metformin and insulin can manage hyperglycemia effectively, but they do little to reverse the underlying causes of the disease, such as chronic inflammation, adipose tissue dysfunction, and gut microbiota imbalances. Moreover, the reductionist approach often neglects drug x drug and drug x genetic interactions. Patients with chronic diseases frequently take multiple medications, yet clinical trials rarely explore how these drugs interact within the context of a diseased system. The result is a healthcare model that treats isolated symptoms while leaving the systemic disease mechanisms untouched.
Emergent Behaviors and Feedback Loops
One of the most significant shortcomings of reductionism is its inability to account for emergent behaviors—properties that arise from the interactions of a system’s components but cannot be predicted by studying those components in isolation. In chronic diseases, emergent behaviors often manifest as tipping points or phase transitions, where incremental changes lead to sudden and dramatic shifts in the system’s state.
For instance, in cardiovascular disease, the accumulation of arterial plaque may proceed gradually until a threshold is reached, triggering a cascade of inflammatory responses and culminating in a heart attack or stroke. Similarly, in diabetes, the gradual loss of beta-cell function may remain compensated for years until the system collapses into a state of overt hyperglycemia. Reductionist approaches fail to anticipate these transitions because they ignore the feedback loops and interdependencies that govern the system.
Feedback loops further complicate the picture. Positive feedback mechanisms, such as the amplification of inflammation in autoimmune disorders, can drive disease progression, while negative feedback mechanisms, such as hormonal counter-regulation in metabolism, can fail over time. Understanding these loops requires a systems-level perspective that reductionism simply cannot provide.
The Consequences of Fragmented Understanding
The failure of reductionism has far-reaching implications for both research and clinical practice. By focusing on individual components, scientists and clinicians often miss opportunities to intervene at the system level. For example, obesity is frequently treated as a simple energy imbalance, with interventions aimed at reducing caloric intake or increasing expenditure. This approach overlooks the hormonal, inflammatory, and psychological factors that perpetuate weight gain, leading to high rates of treatment failure.
Similarly, autoimmune diseases are often managed by suppressing immune activity with drugs like corticosteroids or biologics. While these treatments can reduce symptoms, they do not address the upstream factors—such as epigenetic changes or environmental triggers like aluminum—that drive immune dysregulation. This fragmented approach not only limits the effectiveness of interventions but also perpetuates a cycle of dependency on lifelong symptom management.
The Need for a Paradigm Shift
To truly address chronic illnesses, we must move beyond reductionism and adopt a complexity-based framework. This means embracing systems thinking, where diseases are understood as the product of dynamic interactions between genes, proteins, behaviors, and environments. It also means prioritizing research methodologies that account for nonlinear dynamics, such as network analysis and computational modeling.
A complexity-based approach would fundamentally change how we design interventions. Rather than targeting single pathways, treatments would aim to restore balance across entire networks. Lifestyle interventions, such as dietary changes and stress management, exemplify this principle by targeting multiple systems simultaneously. For example, intermittent fasting not only improves insulin sensitivity but also reduces inflammation, promotes autophagy, and reshapes the gut microbiota—addressing the root causes of metabolic dysfunction.
Reductionism has served as a valuable tool for advancing biomedical science, but its limitations are increasingly evident in the study of chronic diseases. By focusing on isolated components, it fails to capture the complexity of dynamic systems, leading to fragmented understanding and suboptimal interventions. To meet the challenges of the chronic illness epidemic, we must embrace a paradigm that recognizes the interconnectedness of biological, behavioral, and environmental factors. Only by understanding the whole system can we hope to develop interventions that are truly transformative.
A New Framework: Integrative Pathways to Health (IP2H)
Chronic illnesses present one of the greatest challenges to modern medicine. They do not arise from isolated causes or linear mechanisms but emerge from the dynamic interplay of genetic, environmental, behavioral, and systemic factors. Yet, traditional approaches to understanding and treating these diseases remain tethered to reductionism, focusing narrowly on individual pathways or single interventions. To address this gap, the Integrative Pathways to Health (IP2H) framework proposes a unifying, systems-based approach that bridges the divide between holistic and allopathic medicine. By combining the strengths of both traditions, IP2H offers a pathway to uncovering patentable process protocols that address the root causes of chronic diseases, rather than merely managing symptoms.
Breaking Reductionist Paradigms: Toward Integration
Reductionism has been a powerful tool for advancing our understanding of molecular biology and disease mechanisms. However, when applied to chronic illnesses, it often reduces complex phenomena to oversimplified models. This approach has yielded treatments that target specific symptoms, like glucose-lowering drugs for diabetes or statins for high cholesterol, but these interventions frequently fail to address the systemic dysfunctions that drive disease progression.
The IP2H framework moves beyond this fragmentation, integrating holistic and allopathic approaches to capture the full scope of chronic disease dynamics. Holistic medicine emphasizes treating the whole person—mind, body, and environment—recognizing that health is shaped by interconnected systems. Allopathic medicine, with its rigorous evidence base and advanced interventions, provides powerful tools for targeting specific disease mechanisms. By synthesizing these perspectives, IP2H seeks to create a framework that acknowledges the complexity of disease and the need for multifaceted solutions.
Patentable Process Protocols: Innovating Integrated Interventions
At the heart of IP2H is the concept of patentable process protocols—methodologies that combine pharmacological, behavioral, and systems-level interventions into cohesive treatment pathways. These protocols are not merely collections of individual treatments but are designed to leverage the interactions between interventions to amplify their effectiveness.
For example, a protocol for managing Type 2 diabetes might combine:
Pharmacological Interventions: Anti-inflammatory drugs or GLP-1 agonists that target systemic inflammation and improve insulin sensitivity.
Dietary Strategies: Intermittent fasting or low-carbohydrate diets that address metabolic imbalances while reducing the burden on pancreatic beta cells.
Holistic Practices: Mindfulness-based stress reduction (MBSR) or yoga to mitigate the effects of chronic stress on blood sugar and systemic inflammation.
Behavioral Modifications: Tailored physical activity programs designed to improve mitochondrial function and enhance metabolic flexibility.
In autoimmune disorders, an IP2H protocol might integrate epigenetic therapies, gut microbiome modulation, and acupuncture to restore immune balance while addressing chronic inflammation. These protocols are innovative because they create synergies between allopathic and holistic interventions, moving beyond symptom management to address the root causes of disease.
Feedback Loops and Leverage Points: Unlocking Systemic Shifts
Chronic illnesses often progress through feedback loops—self-reinforcing cycles that exacerbate dysfunction. For example, in diabetes, hyperglycemia damages beta cells, reducing insulin production and further worsening blood sugar control. Similarly, in autoimmune diseases, chronic inflammation damages tissues, releasing self-antigens that provoke further immune activation.
IP2H focuses on identifying leverage points—critical junctures where targeted interventions can disrupt these feedback loops and restore systemic balance. Integrating holistic approaches, such as meditation or dietary adjustments, with pharmacological treatments can enhance the body's natural resilience. For instance, meditation has been shown to reduce inflammatory cytokines, while specific dietary patterns can modify the gut microbiota, which plays a key role in immune modulation. These interventions, when paired with allopathic treatments, create opportunities to shift the body from a state of disease to one of health.
Emergent Pathways and Personalized Care
Chronic illnesses are not static but evolve through emergent behaviors—patterns that arise from the interactions of multiple systems. These behaviors are influenced by individual genetic predispositions, environmental exposures, and lifestyle factors, making every case unique. Traditional precision medicine focuses on tailoring treatments based on genetic profiles, but IP2H goes further, incorporating holistic practices and environmental modifications into personalized care plans.
For example, a cardiovascular disease patient with high stress levels might benefit from a protocol that includes mindfulness training to lower blood pressure, alongside statins to reduce cholesterol. Another patient with the same condition but a different underlying profile—such as chronic inflammation—might require dietary interventions and omega-3 supplementation in combination with anti-inflammatory drugs. By addressing the full spectrum of factors influencing disease, IP2H enables truly individualized care.
Integrating Holistic and Allopathic Medicine: A New Research Frontier
Research into the integration of holistic and allopathic medicine has revealed the potential for significant synergies. Studies on mindfulness, for instance, have demonstrated reductions in inflammatory markers such as C-reactive protein (CRP), suggesting a mechanism by which stress reduction can complement pharmacological treatments. Similarly, research on acupuncture has shown its ability to modulate the autonomic nervous system, making it a valuable adjunct in managing chronic pain and inflammation.
Despite these promising findings, significant gaps remain. Many holistic practices lack the rigorous clinical trials that underpin allopathic medicine, while allopathic approaches often overlook the systemic benefits of holistic therapies. IP2H bridges this divide by designing protocols that incorporate the strengths of both traditions, with an emphasis on empirical validation. For example, a trial comparing the combined effects of intermittent fasting, mindfulness, and anti-inflammatory drugs on diabetes progression could yield insights into how these interventions interact and amplify one another.
This research frontier also highlights the importance of cultural and patient-centered considerations. Holistic practices often align with patients' values and beliefs, improving adherence and satisfaction. By integrating these practices into evidence-based frameworks, IP2H not only enhances clinical outcomes but also fosters trust and collaboration between patients and providers.
Toward a Unified Vision of Health
The Integrative Pathways to Health framework represents a paradigm shift in how we approach chronic illness. By combining the rigor of allopathic medicine with the systemic insights of holistic practices, IP2H addresses the root causes of disease while creating innovative, patentable protocols that leverage the strengths of both traditions. This integration is not merely a theoretical exercise but a practical strategy for unlocking new pathways to health, empowering patients, and transforming the future of medicine.
IP2H’s success depends on embracing complexity, fostering interdisciplinary research, and prioritizing patient-centered care. By breaking down the artificial barriers between holistic and allopathic medicine, this framework has the potential to revolutionize healthcare, creating a unified vision of health that is as comprehensive as the diseases it seeks to address.
Rethinking Medical Research: A Four-Year Agenda for NIH Funding
The chronic illness epidemic reveals critical flaws in the paradigms that guide medical research. Traditional reductionist approaches, while invaluable for elucidating molecular mechanisms, are ill-suited to address complex, multifactorial diseases. The next four years of NIH funding must focus on transforming medical research through a systems-based approach—one that integrates complexity science, holistic and allopathic perspectives, and real-world applications. By adopting this agenda, the NIH can drive innovation and provide scalable, effective solutions for managing chronic diseases.
Introduction: The Case for a Paradigm Shift
Chronic diseases such as diabetes, cardiovascular disease, and autoimmune disorders defy simple explanations. These conditions emerge from dynamic interactions among genetic, environmental, behavioral, and systemic factors. Reductionist research often isolates variables or pathways, overlooking the interconnectedness that drives disease progression. The NIH’s four-year agenda must embrace a complexity-informed framework that views chronic illnesses as dynamic, adaptive systems requiring multifaceted interventions.
The proposed agenda builds on the Integrative Pathways to Health (IP2H) framework, emphasizing systems-level research and the integration of holistic and allopathic medicine. This approach will ensure funding prioritizes innovation in methodology, intervention design, and implementation.
Funding Systems-Level Research: Moving Beyond Isolation
Strategic Goal: Fund studies that study chronic diseases as interconnected systems, focusing on interactions, feedback loops, and emergent behaviors.
Traditional research has focused on single factors, such as identifying the role of a gene or protein in a disease. While these studies have been foundational, they fail to address how these factors interact with other systems over time. To correct this, the NIH should:
Fund network analysis studies to map the relationships between genetic, immune, and metabolic factors in diseases like diabetes and rheumatoid arthritis.
Expand support for longitudinal studies that track disease progression over time, capturing temporal dynamics and tipping points.
Develop grants for computational modeling research, enabling researchers to simulate complex disease systems and predict the effects of multifactorial interventions.
For example, funding could support a study on autoimmune diseases that integrates genetic data, microbiome analysis, and environmental triggers into a single systems model. Such research would identify leverage points for intervention, creating pathways for precision-targeted therapies.
Integrating Holistic and Allopathic Approaches
Strategic Goal: Build an evidence base for the combined use of holistic and allopathic interventions in managing chronic diseases.
Holistic medicine offers systemic insights, focusing on treating the whole person, while allopathic medicine excels at precision targeting of disease mechanisms. The NIH must prioritize research that integrates these approaches, addressing skepticism through rigorous methodology. Initiatives could include:
Comparative Effectiveness Trials: Funding studies that evaluate the combined effects of mindfulness practices, dietary changes, and pharmacological treatments. For example, a diabetes trial could compare outcomes for patients receiving only drug therapy versus those receiving a combination of GLP-1 agonists, intermittent fasting, and mindfulness-based stress reduction.
Combined Theraoies Research: Supporting studies to elucidate how alternatives and adjuncts may exhibit force-multiplier synergistic efficacy by targeting complementary systems (immune AND autonomic, for example).
Holistic-Integration Centers: Establish NIH-funded centers to study the systemic effects of holistic AND allopathic interventions, focusing on diseases such as cardiovascular disease, autoimmune disorders, and chronic pain.
Ending Iatrogenic Illness. An earnest program focused on predicting, preventing, mitigating, treating, and reversing chronic illness caused by medicine we'll have the most immediate and lasting impact on health in america.
This agenda not only seeks to enhance the efficacy of interventions but also fosters patient-centered care by aligning medical practices with patient preferences and values.
Innovating Research Methodologies
Strategic Goal: Redesign trial structures to capture the complexity of chronic diseases and real-world conditions.
The current gold standard of randomized controlled trials (RCTs) often fails to accommodate multifactorial interventions. NIH funding should prioritize:
Adaptive Trials: Funding trials that test combinations of interventions and adjust protocols dynamically based on emerging data to learn optimal pathway to health. For instance, a cardiovascular trial could simultaneously evaluate the effects of diet, exercise, and statin therapy, adapting based on participant responses.
Real-World Evidence Studies: Supporting research that uses wearable devices, electronic health records, and patient-reported outcomes to evaluate interventions outside controlled environments.
Process Protocol Validation: Funding projects that refine multifactorial intervention protocols, ensuring their feasibility and scalability for diverse populations.
These methodological innovations will generate findings that are not only rigorous but also applicable to real-world settings, addressing the gap between research and clinical practice.
Translating Research into Action
Strategic Goal: Bridge the gap between research findings and their implementation in clinical and public health settings.
Research is only as impactful as its implementation. The NIH must prioritize funding initiatives that ensure research findings lead to actionable solutions:
Interdisciplinary Collaboration: Creating funding streams for projects that bring together experts from genetics, immunology, nutrition, and behavioral science to co-design integrative interventions.
Patient-Engaged Research: Supporting research programs that involve patients in study design, ensuring that outcomes reflect real-world needs and preferences.
Policy Translation Grants: Funding studies that explore how research findings can inform public health policies, such as workplace wellness programs or community-based health initiatives.
For example, research on the systemic benefits of stress reduction could inform workplace interventions to reduce absenteeism and improve productivity, while findings on dietary interventions could support public policies promoting healthy food access
Conclusion: A Vision for the Future
The NIH’s four-year agenda must embrace a new research paradigm—one that transcends reductionism and integrates complexity science, holistic practices, and real-world evidence. By funding systems-level studies, fostering integrative approaches, and redesigning research methodologies, this agenda can address the root causes of chronic illness, unlocking pathways to transformative solutions.
The NIH has an opportunity to lead the world in rethinking medical research, setting a precedent for how science can address the dynamic, multifactorial nature of disease. This agenda not only advances knowledge but also builds a healthcare system that is more effective, equitable, and patient-centered. By embracing these changes, the NIH can fulfill its mission to improve the health and well-being of all Americans.
We are all ready to see revolutionary reform.
My hope is that your observations will be advanced by the incoming administration. It’s the only way this country can become healthy again.
“Welcome to complex systems,” Bret Weinstein.
A common sense approach like this would be a big improvement for public health, but it won't make a lot of money for the officers and stockholders of large biomedical corporations. The problem with personalized medicine is that it requires smart (well trained, well paid) doctors communicating with their peers, and it doesn't scale very well to produce a good model for industrialized medicine.
Now, the idea of Patentable Process Protocols (while it is currently not legal to patent medical procedures) gestures amicably toward those who need to be able to make money off people's misfortunes, it ultimately is in conflict with the reality personalized medicine. Big Biomedical Science might be helped with computational modeling research, such as is used to model climate change (taking an average of various non-linear scenarios). But this might only be comparably accurate for capturing the idiosyncracies of local conditions. There will be individuals whose unique medical/diet histories lie outside the average, and it will take a dedicated and insightful Dr House-like figure to interpret the evidence as it applies to that unique individual.
If we did away with Big Science and patented medicine entirely, the public would end up being a lot healthier, but the biomedical stock market would collapse. The role of government these days, as I understand it, is to assist corporations, not people. National security and all that.
A government agency should not think like a business; its goal is not to get more customers, expand, and take in more revenue. Its goal is really to try to make itself as unnecessary as possible. How do we put more control in the hands of more individual doctors and researchers, so that HHS doesn't need to implement this blueprint for the way forward? How do we get the way forward to emerge from the local interactions of doctors and researchers who communicate unconstrained by IP laws?